SAN DIEGO & SAN FRANCISCO--(BUSINESS WIRE)--858 Therapeutics and OpenBench today announced a collaboration to discover small molecule inhibitors using OpenBench’s structure-based machine learning ...
SAN DIEGO--(BUSINESS WIRE)--858 Therapeutics today exited stealth mode with a $60 million Series A financing led by founding investor Versant Ventures, with participation from NEA, Cormorant Asset ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback